*Corresponding author:Bakulesh Khamar, Cadila Pharmaceuticals Limited, Cadila Corporate Campus Sarkhej-Dholka Road, Bhat, Ahmedabad, Gujarat, India
Received: August 08, 2018; Published: August 14, 2018
To view the Full Article Peer-reviewed Article PDF
Checkpoint inhibitors have demonstrated efficacy in squamous NSCLC with tolerable toxicity profile. They are used as a monotherapy, in combination with chemotherapy or following chemo-radiotherapy as a first line, second line or consolidation therapy. As a first line, Pembrolizumab improves outcome (PFS) as a monotherapy in patients with PD-L1 expression of ≥ 50% (HR; 0.35). When used with chemotherapy, it improves PFS (HR; 0.56) irrespective of PD-L1 expression level. Nivolumab also improves PFS (HR; 0.62), when used as a second line for those progressing with chemotherapy. Durvalumab improves PFS (HR; 0.68) when used following chemo-radio therapy as a consolidation therapy.
Keywords: Checkpoint Inhibitors; Pembrolizumab; Nivolumab; Atezolizumab; Durvalumab; PD-L1; Squamous NSCLC; Progression Free Survival; Overall Survival
Abstract| Introduction| Checkpoint inhibitors as a Consolidation therapy| Checkpoint Inhibitors as a Second Line Therapy| Checkpoint Inhibitors as a Third Line Therapy| Checkpoint Inhibitors and Management of Squamous NSCLC- Recent Advances| Conclusion| References|
Bio chemistryUniversity of Texas Medical Branch, USA
Department of Criminal JusticeLiberty University, USA
Department of PsychiatryUniversity of Kentucky, USA
Department of MedicineGally International Biomedical Research & Consulting LLC, USA
Department of Urbanisation and AgriculturalMontreal university, USA
Oral & Maxillofacial PathologyNew York University, USA
Gastroenterology and HepatologyUniversity of Alabama, UK
Department of MedicineUniversities of Bradford, UK
OncologyCirculogene Theranostics, England
Radiation ChemistryNational University of Mexico, USA
Analytical ChemistryWentworth Institute of Technology, USA
Minimally Invasive SurgeryMercer University school of Medicine, USA
Pediatric DentistryUniversity of Athens , Greece
The annual scholar awards from Lupine Publishers honor a selected number Read More...
We know the financial complexity of Individual read more...
The annual scholar awards from Lupine Publishers honor a selected number read more...